Marshall Wace, LLP Reata Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$79.22 - $105.37 $26.2 Million - $34.8 Million	-330,446 Reduced 79.63%	84,508 $8.62 Million
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $6.47 Million - $19.5 Million	209,612 Added 102.08%	414,954 $37.7 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $4.28 Million - $8.14 Million	193,342 Added 1611.18%	205,342 $7.8 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $232,920 - $437,880	12,000 New	12,000 $302,000
Q1 2021 May 17, 2021	SELL	$94.25 - $132.81 $991,133 - $1.4 Million	-10,516 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $366,389 - $662,970	3,591 Added 51.86%	10,516 $1.3 Million
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $647,695 - $1.13 Million	6,925 New	6,925 $675,000
Q2 2018 Aug 14, 2018	SELL	$19.94 - $40.96 $211,364 - $434,176	-10,600 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$20.0 - $30.19 $212,000 - $320,014	10,600 New	10,600 $217,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.